Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare

InnoCare Pharma is the latest addition to Eli Lilly’s dealmaking spree, which includes some of the biggest acquisitions this year: up to $7 billion for Kelonia Therapeutics in April and up to $7.8 billion for Centessa Pharmaceuticals in March.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top